
Abstract Background: Response to glucocorticoid (GC) therapy in pemphigus vulgaris (PV) is variable and may be influenced by pharmacogenomic factors. This study aimed to evaluate the association between glutathione S-transferases ( GST ) gene polymorphisms and Multidrug resistance protein 1 ( MDR1 ) or ATP-binding cassette sub-family B member 1 ( ABCB1 ) variations with steroid responsiveness in PV patients and evaluate their role in conferring susceptibility to PV. Patients and Methods: Eighty participants were included: Group A: GC responders (n = 20), Group B: GC nonresponders (n = 20), Group A+B: Combined PV cases (n = 40), and Group C: healthy controls (n = 40). Disease severity was assessed using the Pemphigus Disease Area Index and Dermatology Life Quality Index. Glutathione S-transferase (GST) genotypes, GSTM1 , GSTT1 , and GSTP1 , were analyzed by multiplex polymerase chain reaction (PCR); MDR1 2677G>A/T single nucleotide polymorphism was evaluated by amplification refractory mutation system PCR. MDR1 gene mRNA expression was quantified by reverse transcription-PCR using 18S rRNA as a housekeeping gene. Results: Among the 40 PV patients (mean age: 41.3 ± 13 years; male:female = 21:19), GSTM1 heterozygosity was significantly more frequent (45%) than in controls (28%) ( P = 0.01; odds ratio = 4.636), suggesting its role as a risk factor. GSTT1 heterozygosity was more prevalent in controls (Group C; 58%) than in cases (Group A+B) (32%; P = 0.04), indicating a potential protective role. Among PV patients, nonresponders (Group B) had higher (though statistically non-significant) GSTT1 heterozygosity and combined variant genotypes, and GSTM1 heterozygosity was more frequent in responders (Group A). MDR1 genotype distribution ( 2677G>A/T ) did not differ significantly between groups (A and B); however, downregulated MDR1 mRNA expression was evident in Group A and Group B compared to Group C. Limitations: Small sample size, technical variability in mRNA quantification, and single-population analysis. Conclusion: Heterozygosity in GSTM1 and GSTT1 may influence PV susceptibility and steroid responsiveness. MDR1 expression may correlate with treatment response but requires validation using stable reference genes.
Abstract Background: Autoimmune bullous diseases (AIBD) are chronic mucocutaneous diseases causing a substantial negative impact on the quality of life (QoL) of patients and their caregivers. Aim and Objectives: To study the impact of AIBD and identify the various factors contributing to the decreased QoL of patients and caregivers. Patients and Methods: The study included 65 patients with pemphigus vulgaris or bullous pemphigoid and their caregivers. QoL was assessed using the dermatology life quality index (DLQI) and family dermatology life quality index (FDLQI) questionnaires. The mean life quality index scores were analyzed statistically to identify key factors contributing to the decline in QoL. Results: DLQI score was 13.2 ± 7.1 (mean ± standard deviation) and higher scores were seen if patient had poor education levels ( P = 0.030), active phase of disease ( P < 0.001), severe disease ( P < 0.001), and a fewer (0 to 3) relapses ( P = 0.005). Mean FDLQI score was 13.6 ± 6.4. Patient characteristics that significantly impaired caregiver’s QoL included poor education levels of the patient ( P = 0.041), presence of psychological conditions ( P = 0.010), active disease phase ( P = 0.002), and severe disease ( P < 0.001). Limitations: We did not use disease-specific tools like autoimmune bullous disease quality of life (ABQOL) in assessing QoL. We recognize the potential for interviewer bias in patients requiring translation. The study did not assess the influence of caregiver’s sociodemographic factors on the QoL. Conclusion: AIBD significantly affects the QoL of patients and their caregivers. It is essential to educate, counsel, and provide adequate psychosocial support to the patient and their caregivers.
ABSTRACT Cutaneous cytomegalovirus (CMV) infection is a rare entity, despite a significant seroprevalence of CMV globally. It is most often encountered as an opportunistic infection among immunosuppressed individuals. Skin involvement in CMV infection could be the heralding sign of a more disseminated disease. We report a case series of five immunocompromised patients who manifested varied morphological features of cutaneous CMV infection. All patients were diagnosed based on histopathology, supplemented with immunohistochemistry or serology. The clinical presentations seen in our patients include punched-out ulcers in the perineal region and distal extremities, vesicobullous lesions, truncal ulcers with scalloped margins, crusted hyperpigmented papules, and oral erosions. After a thorough evaluation, patients were initiated on oral valganciclovir or intravenous ganciclovir. Being a rarity, this case series highlights the clinical manifestations and management of cutaneous CMV infection.